Biogen Inc.’s potential game-changing neuroreparative therapy opicinumab (anti-LINGO-1) failed to meet the primary and secondary endpoints of a Phase II trial in patients with multiple sclerosis, highlighting the challenges the company faces developing high-risk, high-reward treatments for serious neurological disorders.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?